Form 4 for KRYS Krystal Biotech, Inc.
Accepted 2022-03-01 00:00:00 ET · period of report 2022-02-26 · accession 0001298709-22-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-01 | 2022-02-26 | KRYS | Krishnan Krish S | Pres, CEO, Dir, 10% | F - Tax | $62.50 | -4,655 | 1.81M | -0.3% | -$290.9K |
| D | 2022-03-01 | 2022-02-28 | KRYS | Krishnan Krish S | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-26 | F | D | 4,655 | $62.50 | 1,813,688 | D | — | — | (F1) Represents tax withholding upon the vesting of 10,200 shares of restricted stock on February 26, 2022. (F2) The closing price on February 25, 2022 of the Company's common stock on NASDAQ. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-02-28 | A | A | 50,000 | $0.00 | 50,000 | D | $63.55 · — to 2032-02-28 | 50,000 Common Stock | (F5) The option vests in four equal annual installments beginning on February 28, 2023. |